Cempra Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Baird Remains Bullish Following Cempra's (CEMP) 4Q; Focus Remains on Solithromycin Launch
February 25, 2016 7:09 AM ESTBaird maintained an Outperform rating on Cempra, Inc. (NASDAQ: CEMP), and cut the price target to $33.00 (from $38.00), following the company's 4Q. Cempra is currently focused on completing regulatory submissions for Solithromycin in CABP and prepping for launch in 2017. As such, the company's 4Q results are... More
Cempra (CEMP) Tops Q4 EPS by 11c
February 24, 2016 4:26 PM ESTCempra (NASDAQ: CEMP) reported Q4 EPS of ($0.48), $0.11 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $5.79 million versus the consensus estimate of $3.89 million.
For earnings history and earnings-related data on Cempra (CEMP) click here.
... More